Skip to main content
OpenTrials

Clinical trial condition

Carcinoma, Non-Small-Cell Lung

Explore clinical trials studying Carcinoma, Non-Small-Cell Lung. Study availability and eligibility vary by location and protocol.

4,683 public trials 1,032 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma, Non-Small-Cell Lung trial results

Active, Not Recruiting

Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.

NCT04823377

Conditions
Advanced Cancer, Bronchial Neoplasms, Carcinoma, Bronchogenic, +8 more
Locations
  • CH Abbeville Abbeville, France
  • CH du Pays d'Aix Aix-en-Provence, France
  • CHU Amiens - Hôpital Sud Amiens, France
  • CHU Angers Angers, France
View all 25 locations
View Trial Details
Active, Not Recruiting

Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer

NCT04940325

Conditions
Advanced Non Small Cell Lung Cancer, Bronchial Neoplasms, Carcinoma, Bronchogenic, +10 more
Locations
  • Institut Bergonié Bordeaux, France
  • Institut de Cancérologie, CHRU Morvan de Brest Brest, France
  • Centre François Baclesse Caen, France
  • Centre Hospitalier Intercommunal de Créteil Créteil, France
View Trial Details
Active, Not Recruiting

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

NCT03052608

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +7 more
Locations
  • Florida Cancer Specialists Altamonte Springs, Florida, United States
  • Florida Cancer Specialists Brandon, Florida, United States
  • Florida Cancer Specialists Clearwater, Florida, United States
  • Florida Cancer Specialists Gainesville, Florida, United States
View all 166 locations
View Trial Details
Active, Not Recruiting

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

NCT06140836

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +7 more
Locations
  • Local Institution - 0221 Des Moines, Iowa, United States
  • Local Institution - 0075 Boston, Massachusetts, United States
  • Local Institution - 0201 Boston, Massachusetts, United States
  • Local Institution - 0210 Mineola, New York, United States
View all 122 locations
View Trial Details
Active, Not Recruiting

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

NCT05238883

Conditions
Adenocarcinoma, Adenoma, Bronchial Neoplasms, +57 more
Locations
  • Mayo Clinic Scottsdale, Arizona, United States
  • USC/Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details
Active, Not Recruiting

Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment

NCT05382052

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Hospital Universitario De A Coruna A Coruña, Spain
  • Hospital General Universitario de Alicante Alicante, Spain
  • Hospital Germans Trias I Pujol Badalona, Barcelona, Spain
  • Hospital Universitari Quiron Dexeus Barcelona, Spain
View all 20 locations
View Trial Details
Active, Not Recruiting

Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy

NCT05781308

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • CHU Amiens Amiens, France
  • CHU d'Angers Angers, France
  • CH Avignon Avignon, France
  • CH Côte Basque Bayonne, France
View all 44 locations
View Trial Details

Related conditions